Literature DB >> 11861659

PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism.

Robert Walczak1, Peter Tontonoz.   

Abstract

The nuclear receptor PPARgamma is a central regulator of adipose tissue development and an important modulator of gene expression in a number of specialized cell types including adipocytes, epithelial cells, and macrophages. PPARgamma signaling pathways impact both cellular and systemic lipid metabolism and have links to obesity, diabetes, and cardiovascular disease. The ability to activate this receptor with small molecule ligands has made PPARgamma an attractive target for intervention in human metabolic disease. As our understanding of PPARgamma biology has expanded, so has the therapeutic potential of PPARgamma ligands. Recent studies have provided insight into the paradoxical relationship between PPARgamma and metabolic disease and established new paradigms for the control of lipid metabolism. This review focuses on recent advances in PPARgamma biology in the areas of adipocyte differentiation, insulin resistance, and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861659

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  57 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Expression of peroxisome proliferator-activated receptors in zebrafish (Danio rerio) depending on gender and developmental stage.

Authors:  Arantza Ibabe; Eider Bilbao; Miren P Cajaraville
Journal:  Histochem Cell Biol       Date:  2004-12-23       Impact factor: 4.304

3.  Effects of different dietary phospholipid levels on growth performance, fatty acid composition, PPAR gene expressions and antioxidant responses of blunt snout bream Megalobrama amblycephala fingerlings.

Authors:  Yang Li; Jian Gao; Songqian Huang
Journal:  Fish Physiol Biochem       Date:  2014-09-27       Impact factor: 2.794

4.  Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma.

Authors:  L Chastine Bell-Parikh; Tomomi Ide; John A Lawson; Peter McNamara; Muredach Reilly; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

5.  Activation of peroxisome proliferator activated receptor-gamma results in an atheroprotective apolipoprotein profile in HepG2 cells.

Authors:  Diala F Dahabreh; Jheem D Medh
Journal:  Adv Biol Chem       Date:  2012-08-22

6.  Association of SIRT1 gene variation with visceral obesity.

Authors:  Armand V Peeters; Sigri Beckers; An Verrijken; Ilse Mertens; Peter Roevens; Pieter J Peeters; Wim Van Hul; Luc F Van Gaal
Journal:  Hum Genet       Date:  2008-09-27       Impact factor: 4.132

Review 7.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

Review 8.  Safety and efficacy of rosiglitazone in the elderly diabetic patient.

Authors:  Adie Viljoen; Alan Sinclair
Journal:  Vasc Health Risk Manag       Date:  2009

9.  De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis.

Authors:  Mohamed Sabry Hamza; Sebastian Pott; Vinsensius B Vega; Jane S Thomsen; Gopalan Srinivasan Kandhadayar; Patrick Wei Pern Ng; Kuo Ping Chiu; Sven Pettersson; Chia Lin Wei; Yijun Ruan; Edison T Liu
Journal:  PLoS One       Date:  2009-03-20       Impact factor: 3.240

10.  Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures.

Authors:  Takuji Oyama; Kenji Toyota; Tsuyoshi Waku; Yuko Hirakawa; Naoko Nagasawa; Jun Ichi Kasuga; Yuichi Hashimoto; Hiroyuki Miyachi; Kosuke Morikawa
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.